• Login
    View Item 
    •   UTMB Health SHARED Home
    • Electronic Theses and Dissertations
    • Published ETD Collection
    • View Item
    •   UTMB Health SHARED Home
    • Electronic Theses and Dissertations
    • Published ETD Collection
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    PEGylated Tissue Repair Peptide TP508 Derivatives as Second Generation Drugs for Radiomitigation and Other Systemic Applications

    Thumbnail
    View/Open
    MCVICAR-DISSERTATIONDOCTORAL-2016.pdf (5.737Mb)
    Author
    Mcvicar, Scott Davenport
    0000-0001-6973-9004
    Metadata
    Show full item record
    Abstract
    TP508 is a therapeutic peptide that represents a specific receptor-binding domain of human thrombin with many potential clinical applications. However, it shares several weaknesses common to peptides when administered systemically, such as a short circulating half-life and rapid proteolytic degradation. One FDA-approved method for modifying therapeutic peptides and small proteins to improve these characteristics is through covalent attachment to polyethylene glycol moieties, a process known as PEGylation. Because TP508 is currently being evaluated as a nuclear countermeasure drug for radiomitigation, this project was initiated to evaluate several different PEGylated TP508 derivatives in an attempt to increase TP508 efficacy or decrease the therapeutic dose required for efficacy. We demonstrate that the circulating half-life of TP508 derivatives increase in a size-dependent manner with the length of polyethylene glycol attached to TP508. The PEGylated TP508 derivatives were evaluated for biological activity to determine if increased half-life correlated with increased activity using a combination of in vitro and in vivo methods. In vitro activity of TP508 derivatives was demonstrated in human dermal microvascular endothelial cells (HDMEC) where TP508 and its derivatives accelerated repair of radiation induced DNA double strand breaks. To test in vivo activity, murine models for mitigation of ionizing radiation using outbred male CD-1 mice were used. These studies demonstrated that injection of only two of the TP508 derivatives enhanced aortic explant angiogenesis when the explants were cultured on extracellular matrix ex vivo. Moreover, equimolar doses of TP508 and two of the TP508 derivatives injected intraperitoneally into male CD-1 mice 24h after receiving 8Gy ionizing radiation showed enhanced closure of full-thickness dorsal excisions, with the PEGylated TP508 derivatives restoring the wound healing rate to that of unirradiated mice. These results have identified two TP508 derivatives that may be promising second-generation drugs for radiomitigation and tissue repair applications where the peptide must be administered systemically.
    URI
    https://hdl.handle.net/2152.3/10734
    Collections
    • Published ETD Collection

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV
     

     

    Browse

    All of UTMB Health SHAREDCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy DepartmentThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Department

    My Account

    Login

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV